Modeling Stromal Cells Inside the Tumor Microenvironment of Ovarian Cancer: In Vitro Generation of Cancer-Associated Fibroblast-Like Cells and Their Impact in a 3D Model

Abstract

The tumor microenvironment (TME) is the combination of cells and factors that promotes tumor progression, and cancer-associated fibroblasts (CAFs) are a key component within TME. CAF originates from various stromal cells and is activated by factors such as transforming growth factor-beta (TGF-β) secreted by tumor cells, favoring chemoresistance and metastasis. Recent publications have underlined plasticity and heterogeneity and their strong contribution to the reactive stroma within the TME. Our study aimed to replicate the TME's structure by creating a 3D in vitro model of ovarian cancer (OC). By incorporating diverse tumor and stromal cells, we simulated a physiologically relevant environment for studying CAF-like cell behavior within tumor spheroids in a context-dependent manner. CAF-like cells were generated by exposing human dermal fibroblasts to OC cell line conditioned media in the presence or absence of TGF-β. Herein, we found that different stimuli induce the generation of heterogeneous populations of CAF-like cells. Notably, we observed the ability of CAF-like cells to shape the intratumoral architecture and to contribute to functional changes in tumor cell behavior. This study highlights the importance of precise assessment of CAF for potential therapeutic interventions and further provides a reliable model for investigating novel therapeutic targets in OC.

Keywords

3D model / cancer-associated fibroblast / ovarian cancer / tumor microenvironment

References

[1] E. Sahai, I. Astsaturov, E. Cukierman, et al., “A Framework for Advancing Our Understanding of Cancer-Associated Fibroblasts,” Nature Reviews Cancer 20, no. 3 (2020): 174-186.

[2] R. Kalluri, “The Biology and Function of Fibroblasts in Cancer,” Nature Reviews Cancer 16, no. 9 (2016): 582-598.

[3] A. Maia, A. Schollhorn, J. Schuhmacher, and C. Gouttefangeas, “CAF-Immune Cell Crosstalk and Its Impact in Immunotherapy,” Seminars in Immunopathology 45, no. 2 (2023): 203-214.

[4] F. Pelon, B. Bourachot, Y. Kieffer, et al., “Cancer-Associated Fibroblast Heterogeneity in Axillary Lymph Nodes Drives Metastases in Breast Cancer Through Complementary Mechanisms,” Nature Communications 11, no. 1 (2020): 404.

[5] J. Winkler, A. Abisoye-Ogunniyan, K. J. Metcalf, and Z. Werb, “Concepts of Extracellular Matrix Remodelling in Tumour Progression and Metastasis,” Nature Communications 11, no. 1 (2020): 5120.

[6] A. Labernadie, T. Kato, A. Brugues, et al., “A Mechanically Active Heterotypic E-Cadherin/N-Cadherin Adhesion Enables Fibroblasts to Drive Cancer Cell Invasion,” Nature Cell Biology 19, no. 3 (2017): 224-237.

[7] C. X. Dominguez, S. Muller, S. Keerthivasan, et al., “Single-Cell RNA Sequencing Reveals Stromal Evolution Into LRRC15⁺ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy,” Cancer Discovery 10, no. 2 (2020): 232-253.

[8] Y. Kieffer, H. R. Hocine, G. Gentric, et al., “Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer,” Cancer Discovery 10, no. 9 (2020): 1330-1351.

[9] D. Lazard, X. Sastre, M. G. Frid, M. A. Glukhova, J. P. Thiery, and V. E. Koteliansky, “Expression of Smooth Muscle-Specific Proteins in Myoepithelium and Stromal Myofibroblasts of Normal and Malignant Human Breast Tissue,” Proceedings of the National Academy of Sciences of the United States of America 90, no. 3 (1993): 999-1003.

[10] X. Li, Z. Sun, G. Peng, et al., “Single-Cell RNA Sequencing Reveals a Pro-Invasive Cancer-Associated Fibroblast Subgroup Associated With Poor Clinical Outcomes in Patients With Gastric Cancer,” Theranostics 12, no. 2 (2022): 620-638.

[11] H. Zheng, H. Liu, Y. Ge, and X. Wang, “Integrated Single-Cell and Bulk RNA Sequencing Analysis Identifies a Cancer Associated Fibroblast-Related Signature for Predicting Prognosis and Therapeutic Responses in Colorectal Cancer,” Cancer Cell International 21, no. 1 (2021): 552.

[12] M. Bartoschek, N. Oskolkov, M. Bocci, et al., “Spatially and Functionally Distinct Subclasses of Breast Cancer-Associated Fibroblasts Revealed by Single Cell RNA Sequencing,” Nature Communications 9, no. 1 (2018): 5150.

[13] T. Zhang, Y. Ren, P. Yang, J. Wang, and H. Zhou, “Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma,” Cell Death & Disease 13, no. 10 (2022): 897.

[14] H. Yoon, C. M. Tang, S. Banerjee, et al., “TGF-β1-Mediated Transition of Resident Fibroblasts to Cancer-Associated Fibroblasts Promotes Cancer Metastasis in Gastrointestinal Stromal Tumor,” Oncogenesis 10, no. 2 (2021): 13.

[15] V. S. LeBleu and R. Kalluri, “A Peek Into Cancer-Associated Fibroblasts: Origins, Functions and Translational Impact,” Disease Models & Mechanisms 11, no. 4 (2018): dmm029447.

[16] M. D. Castellone and L. MO, “TGF-β1, WNT, and SHH Signaling in Tumor Progression and in Fibrotic Diseases,” Frontiers in Bioscience 9, no. 1 (2017): 31-45.

[17] Q. Luo, J. Liu, Q. Fu, et al., “Identifying Cancer Cell-Secreted Proteins That Activate Cancer-Associated Fibroblasts as Prognostic Factors for Patients With Pancreatic Cancer,” Journal of Cellular and Molecular Medicine 26, no. 22 (2022): 5657-5669.

[18] E. Elyada, M. Bolisetty, P. Laise, et al., “Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts,” Cancer Discovery 9, no. 8 (2019): 1102-1123.

[19] E. Wagenblast, M. Soto, S. Gutierrez-Angel, et al., “A Model of Breast Cancer Heterogeneity Reveals Vascular Mimicry as a Driver of Metastasis,” Nature 520, no. 7547 (2015): 358-362.

[20] J. Zhao, “Cancer Stem Cells and Chemoresistance: The Smartest Survives the Raid,” Pharmacology & Therapeutics 160 (2016): 145-158.

[21] N. Nair, A. S. Calle, M. H. Zahra, et al., “A Cancer Stem Cell Model as the Point of Origin of Cancer-Associated Fibroblasts in Tumor Microenvironment,” Scientific Reports 7, no. 1 (2017): 6838.

[22] W. J. Chen, C. C. Ho, Y. L. Chang, et al., “Cancer-Associated Fibroblasts Regulate the Plasticity of Lung Cancer Stemness via Paracrine Signalling,” Nature Communications 5 (2014): 3472.

[23] E. Giannoni, F. Bianchini, L. Masieri, et al., “Reciprocal Activation of Prostate Cancer Cells and Cancer-Associated Fibroblasts Stimulates Epithelial-Mesenchymal Transition and Cancer Stemness,” Cancer Research 70, no. 17 (2010): 6945-6956.

[24] Z. Ma, X. Li, Y. Mao, et al., “Interferon-Dependent SLC14A1⁺ Cancer-Associated Fibroblasts Promote Cancer Stemness via WNT5A in Bladder Cancer,” Cancer Cell 40, no. 12 (2022): 1550-1565.

[25] Y. Li, R. Wang, S. Xiong, et al., “Cancer-Associated Fibroblasts Promote the Stemness of CD24⁺ Liver Cells via Paracrine Signaling,” Journal of Molecular Medicine 97, no. 2 (2019): 243-255.

[26] B. Yu, K. Wu, X. Wang, et al., “Periostin Secreted by Cancer-Associated Fibroblasts Promotes Cancer Stemness in Head and Neck Cancer by Activating Protein Tyrosine Kinase 7,” Cell Death & Disease 9, no. 11 (2018): 1082.

[27] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[28] M. Hornburg, M. Desbois, S. Lu, et al., “Single-Cell Dissection of Cellular Components and Interactions Shaping the Tumor Immune Phenotypes in Ovarian Cancer,” Cancer Cell 39, no. 7 (2021): 928-944.

[29] R. Zou, Q. Jiang, T. Jin, M. Chen, L. Yao, and H. Ding, “Pan-Cancer Analyses and Molecular Subtypes Based on the Cancer-Associated Fibroblast Landscape and Tumor Microenvironment Infiltration Characterization Reveal Clinical Outcome and Immunotherapy Response in Epithelial Ovarian Cancer,” Frontiers in Immunology 13 (2022): 956224.

[30] C. S. Leung, T. L. Yeung, K. P. Yip, et al., “Calcium-Dependent FAK/CREB/TNNC1 Signalling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential,” Nature Communications 5 (2014): 5092.

[31] G. Hu, S. Wang, F. Xu, et al., “Tumor-Infiltrating Podoplanin⁺ Fibroblasts Predict Worse Outcome in Solid Tumors,” Cellular Physiology and Biochemistry 51, no. 3 (2018): 1041-1050.

[32] Y. Duan, X. Zhang, H. Ying, et al., “Targeting MFAP5 in Cancer-Associated Fibroblasts Sensitizes Pancreatic Cancer to PD-L1-Based Immunochemotherapy via Remodeling the Matrix,” Oncogene 42, no. 25 (2023): 2061-2073.

[33] Y. Zhang, H. Tang, J. Cai, et al., “Ovarian Cancer-Associated Fibroblasts Contribute to Epithelial Ovarian Carcinoma Metastasis by Promoting Angiogenesis, Lymphangiogenesis and Tumor Cell Invasion,” Cancer Letters 303, no. 1 (2011): 47-55.

[34] Q. Han, B. Huang, Z. Huang, et al., “Tumor Cell‑Fibroblast Heterotypic Aggregates in Malignant Ascites of Patients With Ovarian Cancer,” International Journal of Molecular Medicine 44, no. 6 (2019): 2245-2255.

[35] S. Capellero, J. Erriquez, C. Battistini, et al., “Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells,” International Journal of Molecular Sciences 23, no. 2 (2022): 833.

[36] L. B. Tofani, L. O. Sousa, M. T. Luiz, et al., “Generation of a Three-Dimensional In Vitro Ovarian Cancer Co-Culture Model for Drug Screening Assays,” Journal of Pharmaceutical Sciences 110, no. 7 (2021): 2629-2636.

[37] Y. Fang, X. Xiao, J. Wang, et al., “Cancer Associated Fibroblasts Serve as an Ovarian Cancer Stem Cell Niche Through Noncanonical Wnt5a Signaling,” NPJ Precision Oncology 8, no. 1 (2024): 7.

[38] B. C. Jena, S. Sarkar, L. Rout, and M. Mandal, “The Transformation of Cancer-Associated Fibroblasts: Current Perspectives on the Role of TGF-β in CAF Mediated Tumor Progression and Therapeutic Resistance,” Cancer Letters 520 (2021): 222-232.

[39] A. Miyamoto, L. J. Donovan, E. Perez, et al., “Binding of MAGP2 to Microfibrils Is Regulated by Proprotein Convertase Cleavage,” Matrix Biology 40 (2014): 27-33.

[40] Q. Peng, L. Zhao, Y. Hou, et al., “Biological Characteristics and Genetic Heterogeneity Between Carcinoma-Associated Fibroblasts and Their Paired Normal Fibroblasts in Human Breast Cancer,” PLoS One 8, no. 4 (2013): e60321.

[41] D. Ohlund, A. Handly-Santana, G. Biffi, et al., “Distinct Populations of Inflammatory Fibroblasts and Myofibroblasts in Pancreatic Cancer,” Journal of Experimental Medicine 214, no. 3 (2017): 579-596.

[42] G. Pelaia, L. Gallelli, B. D'Agostino, et al., “Effects of TGF-β and Glucocorticoids on Map Kinase Phosphorylation, IL-6/IL-11 Secretion and Cell Proliferation in Primary Cultures of Human Lung Fibroblasts,” Journal of Cellular Physiology 210, no. 2 (2007): 489-497.

[43] X. Zhang and Y. S. Hwang, “Cancer-Associated Fibroblast Stimulates Cancer Cell Invasion in an Interleukin-1 Receptor (IL-1R)-Dependent Manner,” Oncology Letters 18, no. 5 (2019): 4645-4650.

[44] Y. Chen, L. Huang, R. H. Gan, et al., “IL-8 Activates Fibroblasts to Promote the Invasion of HNSCC Cells via STAT3-MMP1,” Cell Death Discovery 10, no. 1 (2024): 65.

[45] N. Erez, M. Truitt, P. Olson, A. ST, and D. Hanahan, “Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner,” Cancer Cell 17, no. 2 (2010): 135-147.

[46] Y. Li, R. Tian, J. Liu, et al., “Deciphering the Immune Landscape Dominated by Cancer-Associated Fibroblasts to Investigate Their Potential in Indicating Prognosis and Guiding Therapeutic Regimens in High Grade Serous Ovarian Carcinoma,” Frontiers in Immunology 13 (2022): 940801.

[47] T. L. Yeung, C. S. Leung, K. K. Wong, et al., “TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment,” Cancer Research 73, no. 16 (2013): 5016-5028.

[48] J. Zhang, S. Lu, T. Lu, et al., “Single-Cell Analysis Reveals the COL11A1⁺ Fibroblasts Are Cancer-Specific Fibroblasts That Promote Tumor Progression,” Frontiers in Pharmacology 14 (2023): 1121586.

[49] Q. Gao, Z. Yang, S. Xu, et al., “Heterotypic CAF-Tumor Spheroids Promote Early Peritoneal Metastatis of Ovarian Cancer,” Journal of Experimental Medicine 216, no. 3 (2019): 688-703.

[50] W. Li, X. Zhang, J. Wang, et al., “TGFβ1 in Fibroblasts-Derived Exosomes Promotes Epithelial-Mesenchymal Transition of Ovarian Cancer Cells,” Oncotarget 8, no. 56 (2017): 96035-96047.

[51] C. L. Au Yeung, N. N. Co, T. Tsuruga, et al., “Exosomal Transfer of Stroma-Derived miR21 Confers Paclitaxel Resistance in Ovarian Cancer Cells Through Targeting APAF1,” Nature Communications 7 (2016): 11150.

[52] P. J. Mishra, P. J. Mishra, R. Humeniuk, et al., “Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells,” Cancer Research 68, no. 11 (2008): 4331-4339.

[53] R. A. Salah, M. A. Nasr, A. M. El-Derby, et al., “Hepatocellular Carcinoma Cell Line-Microenvironment Induced Cancer-Associated Phenotype, Genotype and Functionality in Mesenchymal Stem Cells,” Life Sciences 288 (2022): 120168.

[54] T. Hu and J. Hu, “Melanoma-Derived Exosomes Induce Reprogramming Fibroblasts Into Cancer-Associated Fibroblasts via Gm26809 Delivery,” Cell Cycle 18, no. 22 (2019): 3085-3094.

[55] Y. Cui, D. Wang, and M. Xie, “Tumor-Derived Extracellular Vesicles Promote Activation of Carcinoma-Associated Fibroblasts and Facilitate Invasion and Metastasis of Ovarian Cancer by Carrying miR-630,” Frontiers in Cell and Developmental Biology 9 (2021): 652322.

[56] B. C. Ozdemir, T. Pentcheva-Hoang, J. L. Carstens, et al., “Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer With Reduced Survival,” Cancer Cell 25, no. 6 (2014): 719-734.

[57] L. Micallef, N. Vedrenne, F. Billet, B. Coulomb, I. A. Darby, and A. Desmouliere, “The Myofibroblast, Multiple Origins for Major Roles in Normal and Pathological Tissue Repair,” Fibrogenesis Tissue Repair, supplement 5, no. S1 (2012): S5.

[58] Y. Tai, E. L. Woods, J. Dally, et al., “Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis,” Biomolecules 11, no. 8 (2021): 1095.

[59] Y. Chen, K. M. McAndrews, and R. Kalluri, “Clinical and Therapeutic Relevance of Cancer-Associated Fibroblasts,” Nature Reviews Clinical Oncology 18, no. 12 (2021): 792-804.

[60] A. V. Shinde, C. Humeres, and N. G. Frangogiannis, “The Role of α-Smooth Muscle Actin in Fibroblast-Mediated Matrix Contraction and Remodeling,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1863, no. 1 (2017): 298-309.

[61] J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown, “Myofibroblasts and Mechano-Regulation of Connective Tissue Remodelling,” Nature Reviews Molecular Cell Biology 3, no. 5 (2002): 349-363.

[62] A. M. Givel, Y. Kieffer, A. Scholer-Dahirel, et al., “miR200-regulated CXCL12β Promotes Fibroblast Heterogeneity and Immunosuppression in Ovarian Cancers,” Nature Communications 9, no. 1 (2018): 1056.

[63] Y. Wang, R. Wang, B. Li, et al., “Cancer-Associated Fibroblasts in the Invasive Tumour front Promote the Metastasis of Oral Squamous Cell Carcinoma Through MFAP5 Upregulation,” Gene 876 (2023): 147504.

[64] B. Erdogan, M. Ao, L. M. White, et al., “Cancer-Associated Fibroblasts Promote Directional Cancer Cell Migration by Aligning Fibronectin,” Journal of Cell Biology 216, no. 11 (2017): 3799-3816.

[65] A. Mestre-Farrera, M. Bruch-Oms, R. Pena, et al., “Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion,” Cancer Research 81, no. 2 (2021): 438-451.

[66] Z. Guo, H. Zhang, Y. Fu, et al., “Cancer-Associated Fibroblasts Induce Growth and Radioresistance of Breast Cancer Cells Through Paracrine IL-6,” Cell Death Discovery 9, no. 1 (2023): 6.

[67] H. Amer, N. C. Kampan, C. Itsiopoulos, et al., “Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies,” Cancers 16, no. 24 (2024): 418.

[68] F. Baschieri, A. Illand, J. Barbazan, et al., “Fibroblasts Generate Topographical Cues That Steer Cancer Cell Migration,” Science Advances 9, no. 33 (2023): eade2120.

[69] O. Eickelberg, A. Pansky, R. Mussmann, et al., “Transforming Growth Factor-β1 Induces Interleukin-6 Expression via Activating Protein-1 Consisting of JunD Homodimers in Primary Human Lung Fibroblasts,” Journal of Biological Chemistry 274, no. 18 (1999): 12933-12938.

[70] Z. Yao, S. Fenoglio, D. C. Gao, et al., “TGF-β IL-6 Axis Mediates Selective and Adaptive Mechanisms of Resistance to Molecular Targeted Therapy in Lung Cancer,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 35 (2010): 15535-15540.

[71] D. L. Bourgeois, K. A. Kabarowski, V. L. Porubsky, and P. K. Kreeger, “High-Grade Serous Ovarian Cancer Cell Lines Exhibit Heterogeneous Responses to Growth Factor Stimulation,” Cancer Cell International 15 (2015): 112.

[72] M. M. Ptaszynska, M. L. Pendrak, R. W. Bandle, M. L. Stracke, and D. D. Roberts, “Positive Feedback Between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells,” Molecular Cancer Research 6, no. 3 (2008): 352-363.

[73] S. Domcke, R. Sinha, D. A. Levine, C. Sander, and N. Schultz, “Evaluating Cell Lines as Tumour Models by Comparison of Genomic Profiles,” Nature Communications 4 (2013): 2126.

[74] G. Biffi, T. E. Oni, B. Spielman, et al., “IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma,” Cancer discovery 9, no. 2 (2019): 282-301.

[75] M. Zhang, Z. Chen, Y. Wang, H. Zhao, and Y. Du, “The Role of Cancer-Associated Fibroblasts in Ovarian Cancer,” Cancers 14, no. 11 (2022): 2637.

[76] C. Neuzillet, R. Nicolle, J. Raffenne, et al., “Periostin- and Podoplanin-Positive Cancer-Associated Fibroblast Subtypes Cooperate to Shape the Inflamed Tumor Microenvironment in Aggressive Pancreatic Adenocarcinoma,” Journal of Pathology 258, no. 4 (2022): 408-425.

[77] J. M. Houthuijzen, R. de Bruijn, E. van der Burg, et al., “CD26-Negative and CD26-Positive Tissue-Resident Fibroblasts Contribute to Functionally Distinct CAF Subpopulations in Breast Cancer,” Nature Communications 14, no. 1 (2023): 183.

[78] I. Yakavets, A. Francois, A. Benoit, J. L. Merlin, L. Bezdetnaya, and G. Vogin, “Advanced Co-Culture 3D Breast Cancer Model for Investigation of Fibrosis Induced by External Stimuli: Optimization Study,” Scientific Reports 10, no. 1 (2020): 21273.

[79] L. Sun, M. Ke, X. Wang, et al., “FAP^high α-SMA^low Cancer-Associated Fibroblast-Derived SLPI Protein Encapsulated in Extracellular Vesicles Promotes Ovarian Cancer Development via Activation of PI3K/AKT and Downstream Signaling Pathways,” Molecular Carcinogenesis 61, no. 10 (2022): 910-923.

[80] B. Z. Xue, W. Xiang, Q. Zhang, et al., “CD90^low Glioma-Associated Mesenchymal Stromal/Stem Cells Promote Temozolomide Resistance by Activating FOXS1-Mediated Epithelial-Mesenchymal Transition in Glioma Cells,” Stem Cell Research & Therapy 12, no. 1 (2021): 394.

[81] A. Svensson, T. Ramos-Moreno, S. Eberstal, S. Scheding, and J. Bengzon, “Identification of Two Distinct Mesenchymal Stromal Cell Populations in Human Malignant Glioma,” Journal of Neuro-Oncology 131, no. 2 (2017): 245-254.

[82] P. J. Asif, C. Longobardi, M. Hahne, and J. P. Medema, “The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis,” Cancers 13, no. 18 (2021): 4720.

[83] R. N. Buick, R. Pullano, and J. M. Trent, “Comparative Properties of Five Human Ovarian Adenocarcinoma Cell Lines,” Cancer Research 45, no. 8 (1985): 3668-3676.

[84] G. J. Lim, S. J. Kang, and J. Y. Lee, “Novel Invasion Indices Quantify the Feed-Forward Facilitation of Tumor Invasion by Macrophages,” Scientific Reports 10, no. 1 (2020): 718.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.